[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Browse LRRTM1

Summary
SymbolLRRTM1
Nameleucine rich repeat transmembrane neuronal 1
Aliases FLJ32082; leucine-rich repeat transmembrane neuronal 1 protein; Leucine-rich repeat transmembrane neuronal p ......
Chromosomal Location2p12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cell membrane Single-pass type I membrane protein Cell junction, synapse, postsynaptic cell membrane Single-pass type I membrane protein
Domain PF13855 Leucine rich repeat
Function

Exhibits strong synaptogenic activity, restricted to excitatory presynaptic differentiation, acting at both pre- and postsynaptic level.

> Gene Ontology
 
Biological Process GO:0001933 negative regulation of protein phosphorylation
GO:0002090 regulation of receptor internalization
GO:0002091 negative regulation of receptor internalization
GO:0006469 negative regulation of protein kinase activity
GO:0006898 receptor-mediated endocytosis
GO:0007259 JAK-STAT cascade
GO:0007416 synapse assembly
GO:0007626 locomotory behavior
GO:0030100 regulation of endocytosis
GO:0031623 receptor internalization
GO:0033673 negative regulation of kinase activity
GO:0035418 protein localization to synapse
GO:0035640 exploration behavior
GO:0042326 negative regulation of phosphorylation
GO:0043112 receptor metabolic process
GO:0044089 positive regulation of cellular component biogenesis
GO:0044708 single-organism behavior
GO:0045806 negative regulation of endocytosis
GO:0046425 regulation of JAK-STAT cascade
GO:0046426 negative regulation of JAK-STAT cascade
GO:0048167 regulation of synaptic plasticity
GO:0048259 regulation of receptor-mediated endocytosis
GO:0048261 negative regulation of receptor-mediated endocytosis
GO:0050803 regulation of synapse structure or activity
GO:0050804 modulation of synaptic transmission
GO:0050806 positive regulation of synaptic transmission
GO:0050807 regulation of synapse organization
GO:0050808 synapse organization
GO:0051051 negative regulation of transport
GO:0051348 negative regulation of transferase activity
GO:0051962 positive regulation of nervous system development
GO:0051963 regulation of synapse assembly
GO:0051965 positive regulation of synapse assembly
GO:0060291 long-term synaptic potentiation
GO:0060627 regulation of vesicle-mediated transport
GO:0097696 STAT cascade
GO:1902532 negative regulation of intracellular signal transduction
GO:1904892 regulation of STAT cascade
GO:1904893 negative regulation of STAT cascade
Molecular Function GO:0004857 enzyme inhibitor activity
GO:0004860 protein kinase inhibitor activity
GO:0019207 kinase regulator activity
GO:0019210 kinase inhibitor activity
GO:0019887 protein kinase regulator activity
Cellular Component GO:0030424 axon
GO:0030426 growth cone
GO:0030427 site of polarized growth
GO:0045211 postsynaptic membrane
GO:0060076 excitatory synapse
GO:0097060 synaptic membrane
GO:0098794 postsynapse
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-6794361: Interactions of neurexins and neuroligins at synapses
R-HSA-112316: Neuronal System
R-HSA-6794362: Protein-protein interactions at synapses
Summary
SymbolLRRTM1
Nameleucine rich repeat transmembrane neuronal 1
Aliases FLJ32082; leucine-rich repeat transmembrane neuronal 1 protein; Leucine-rich repeat transmembrane neuronal p ......
Chromosomal Location2p12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between LRRTM1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolLRRTM1
Nameleucine rich repeat transmembrane neuronal 1
Aliases FLJ32082; leucine-rich repeat transmembrane neuronal 1 protein; Leucine-rich repeat transmembrane neuronal p ......
Chromosomal Location2p12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of LRRTM1 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolLRRTM1
Nameleucine rich repeat transmembrane neuronal 1
Aliases FLJ32082; leucine-rich repeat transmembrane neuronal 1 protein; Leucine-rich repeat transmembrane neuronal p ......
Chromosomal Location2p12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of LRRTM1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.4740.0301
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.3380.506
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.5720.179
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-1.5450.03
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-1.5380.168
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-1.5550.222
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-1.0860.25
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.4210.786
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-1.6650.354
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 4801
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 2801
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.0770.672
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of LRRTM1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27737.407.40.0709
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27597.407.40.096
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.1011.10.36
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59200200.357
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolLRRTM1
Nameleucine rich repeat transmembrane neuronal 1
Aliases FLJ32082; leucine-rich repeat transmembrane neuronal 1 protein; Leucine-rich repeat transmembrane neuronal p ......
Chromosomal Location2p12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of LRRTM1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolLRRTM1
Nameleucine rich repeat transmembrane neuronal 1
Aliases FLJ32082; leucine-rich repeat transmembrane neuronal 1 protein; Leucine-rich repeat transmembrane neuronal p ......
Chromosomal Location2p12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of LRRTM1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by LRRTM1.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolLRRTM1
Nameleucine rich repeat transmembrane neuronal 1
Aliases FLJ32082; leucine-rich repeat transmembrane neuronal 1 protein; Leucine-rich repeat transmembrane neuronal p ......
Chromosomal Location2p12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of LRRTM1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolLRRTM1
Nameleucine rich repeat transmembrane neuronal 1
Aliases FLJ32082; leucine-rich repeat transmembrane neuronal 1 protein; Leucine-rich repeat transmembrane neuronal p ......
Chromosomal Location2p12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of LRRTM1 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolLRRTM1
Nameleucine rich repeat transmembrane neuronal 1
Aliases FLJ32082; leucine-rich repeat transmembrane neuronal 1 protein; Leucine-rich repeat transmembrane neuronal p ......
Chromosomal Location2p12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between LRRTM1 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolLRRTM1
Nameleucine rich repeat transmembrane neuronal 1
Aliases FLJ32082; leucine-rich repeat transmembrane neuronal 1 protein; Leucine-rich repeat transmembrane neuronal p ......
Chromosomal Location2p12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting LRRTM1 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.